Show simple item record

dc.contributor.author Tőkés, Anna-Mária
dc.contributor.author Szász, Attila Marcell
dc.contributor.author Geszti F
dc.contributor.author Lukacs LV
dc.contributor.author Kenessey, István
dc.contributor.author Turányi, Eszter
dc.contributor.author Meggyesházi, Nóra
dc.contributor.author Molnár, István Artúr
dc.contributor.author Fillinger, János
dc.contributor.author Soltesz I
dc.contributor.author Bálint, Katalin
dc.contributor.author Hanzely Z
dc.contributor.author Arato G
dc.contributor.author Szendrői, Miklós
dc.contributor.author Kulka, Janina
dc.date.accessioned 2016-12-14T14:22:47Z
dc.date.available 2016-12-14T14:22:47Z
dc.date.issued 2015
dc.identifier 84924987787
dc.identifier.citation pagination=274-282; journalVolume=68; journalIssueNumber=4; journalTitle=JOURNAL OF CLINICAL PATHOLOGY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/2787
dc.identifier.uri doi:10.1136/jclinpath-2014-202607
dc.description.abstract AIMS: To assess the expression of the following cell cycle regulatory proteins in primary metastatic breast carcinomas (MBCs) and on availability in matched distant metastases (DMs): Ki67, cyclin A, geminin and aurora-kinase A (aurkA); and to compare the expression of these markers in early MBC (EMBC) and late MBC separated into groups according to median time point on metastatic event occurred (28 months). METHODS: The expression of the above mentioned markers was analysed in a total of 47 primary MBCs and 59 DMs (out of which 37 were pairs) by immunohistochemistry. Fourteen breast carcinomas with no relapse over a 10-year follow-up period were utilised as control cases (CBC). RESULTS: Among the MBCs, 22 metastasised to the bone, 4 to the lung and 21 to the central nervous system (CNS). Geminin (p<0.001) and Ki67 (p=0.001) were increased in the MBCs while aurkA and cyclin A showed no difference when compared with CBCs. There were no differences between aurkA, cyclin A and geminin expression in MBCs and DMs in general. Expression of Ki67 was, however, elevated (p=0.027) in DMs. In CNS metastases all markers showed elevated expression as compared to MBCs. In bone metastases, geminin was lower (p<0.001) compared with primary MBCs. In the metastases of the lung, the evaluated markers did not show different expression. According to the median follow-up until the metastatic event, Ki67 was found to be significantly elevated in EMBC (p=0.018). CONCLUSIONS: Ki67 index and geminin distinguish a fraction of MBC with worse prognosis, showing increased levels in the latter in comparison to CBC being tumour-free over a 10-year follow-up period. Ki67 could possibly identify a group of MBCs that develop early DMs.
dc.relation.ispartof urn:issn:0021-9746
dc.title Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.
dc.type Journal Article
dc.date.updated 2015-11-26T08:55:36Z
dc.language.rfc3066 en
dc.identifier.mtmt 2821045
dc.identifier.wos WOS:000351233100005
dc.identifier.pubmed 25595275
dc.contributor.department SE/AOK/I/II. Sz. Patológiai Intézet
dc.contributor.department SE/AOK/I/I. Sz. Patológiai és Kísérleti Rákkutató Intézet
dc.contributor.department SE/AOK/K/Ortopédiai Klinika
dc.contributor.department SE/AOK/K/I. Sz. Sebészeti Klinika
dc.contributor.department SE/AOK/I/IISZPI/MTA-SE Molekuláris Onkológia Kutatócsoport
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote Tőkés Anna-Mária & Szász Attila Marcell are equal first authors


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account